Paul Thomen

Thursday, 25 April 2013

Septic Shock & Ischemic Stroke H1 Pipeline Review 2013

‘Septic Shock & Ischemic Stroke – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Septic Shock & Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Septic Shock & Ischemic Stroke. Septic Shock & Ischemic Stroke– Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

- A snapshot of the global therapeutic scenario for Septic Shock & Ischemic Stroke.
- A review of the Septic Shock & Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Septic Shock & Ischemic Stroke pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Septic Shock & Ischemic Stroke.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Septic Shock & Ischemic Stroke pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Content

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Septic Shock & Ischemic Stroke Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Septic Shock & Ischemic Stroke 9
Septic Shock & Ischemic Stroke Therapeutics under Development by Companies 11
Septic Shock & Ischemic Stroke Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Septic Shock & Ischemic Stroke Therapeutics - Products under Development by Companies 21
Septic Shock & Ischemic Stroke Therapeutics - Products under Investigation by Universities/Institutes 24
Companies Involved in Septic Shock & Ischemic Stroke Therapeutics Development 25
Johnson & Johnson 25
Sanofi-Aventis 26
Eli Lilly and Company 27
Athersys, Inc. 28
H Lundbeck A/S 29
Laboratoires Pierre Fabre SA 30
Mitsubishi Tanabe Pharma Corporation 31
Pfizer Inc. 32
Celgene Corporation 33
Oxygen Biotherapeutics, Inc. 34
Proneuron Biotechnologies, Inc. 35
Neuralstem, Inc. 36
Cytomedix, Inc. 37
ReNeuron Group plc 38
Torrent Pharmaceuticals Limited 39
Pluristem Therapeutics Inc. 40
Stem Cell Therapeutics Corp. 41
NeuroVive Pharmaceutical AB 42
D-Pharm Ltd. 43
SynZyme Technologies, LLC 44
BioMAS Ltd. 45
AGY Therapeutics, Inc. 46
Remedy Pharmaceuticals, Inc. 47
Angion Biomedica Corp. 48
Stemedica Cell Technologies, Inc. 49
M's Science Corporation 50
Manipal AcuNova Ltd 51
Shin Poong Pharm Co., Ltd. 52
Gaia BioPharma Limited 53
Stempeutics Research Private Limited 54

For more details contact Mr. Priyank Tiwari: / +18883915441

No comments:

Post a Comment

Note: only a member of this blog may post a comment.